Compare Citius Pharmaceuticals Inc (CTXR) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Target Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Target Corporation trades at $155.16 (market cap $70.31B). The key difference: Target Corporation is far larger — about 5162.3× Citius Pharmaceuticals Inc's market cap, and Target Corporation pays a 3% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Target Corporation for 137 Days on average.
| CTXR | TGT | |
|---|---|---|
Market Cap | $13.62M | $70.31B |
Volume | 132,438 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $169.90 |
52-Week Low | $0.48 | $83.68 |
Typical Hold Time | 16 Days | 137 Days |
Enterprise Value | $3.79M | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Target Corporation (TGT) trades at $154.56, up 2.38% with strong recent earnings beats and positive analyst sentiment. The stock shows bearish technical signals but maintains solid fundamentals with a 4.08% net margin and 26.41% ROE. Recent price cuts on 2,000 items aim to capture holiday market share, while consistent dividend payments reinforce shareholder returns. Valuation metrics appear reasonable with P/E of 16.05 and P/S of 0.65.
Target presents a balanced opportunity with analyst consensus pointing to 8% upside to the $167.18 price target. The turnaround strategy shows early success, but competitive pressures and margin compression from price investments remain key risks. Institutional support remains strong with 60 analyst coverage favoring buy/hold positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
